GeNeuro will contribute its expertise in human endogenous retroviruses to the EU-funded 6.8 million euro precision medicine project HERVCOV
The R&D subsidiary GeNeuro Innovation, in Lyon, France, was selected for its unique expertise in human endogenous retroviruses
GeNeuro Innovation will contribute to the implementation of diagnostic and therapeutic tools on an industrial scale to treat W-ENV-related syndromes identified from this multidisciplinary study of a large panel of molecular, biological and clinical parameters of patients.
Initially focused on COVID-19 and post-COVID syndromes, this study will also provide insights into other diseases associated with W-ENV, with the aim of providing new precision medicine solutions based on biomarker analysis, symptoms and disease progression.
Project funded by the European Commission with a grant of 6.8 million euros which involves research centres, companies and associations from Croatia, France, Greece, Italy and Spain
GENEVA & LYON, France, June 20, 2022–(BUSINESS WIRE)–Regulatory news:
GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris:GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the consequences term of COVID-19 (post-COVID), announces today that its R&D subsidiary GeNeuro Innovation SAS will be the industrial R&D partner of the HERVCOV project funded by a 6.8 million euro grant from the HORIZON-Health program of the European Union.
The HERVCOV project is funded by a grant under the HORIZON-HLTH-2021-DISEASE (Personalized medicine and infectious diseases: understanding the individual host response to viruses) call from the European Commission under the program- Horizon Europe framework. The partners are the National Institute of Health and Medical Research (France), Ethniko Kai Kapodistriako Panepistimio Athinon (Greece), the University of Rome Tor Vergata (Italy), the Instituto Aragonés de Ciencias de la Salud (Spain ), the Fundación Agencia Aragonesa para la Investigación y el Desarrollo (Spain), GeNeuro Innovation SAS (France), Inserm Transfert (France), Klinicki Bolnicki Centar Rijeka (Croatia) and Frascati Scienza (Italy).
“GeNeuro Innovation will collaborate with its multidisciplinary partners to develop industrial-grade decentralized W-ENV diagnostic tools, opening the door to personalized treatment in large populations affected by W-ENV expression, from post-COVID-19 to other potentially post-viral illnesses. with overlapping symptoms, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)“, said Hervé Perron, scientific director of GeNeuro.
“GeNeuro Innovation’s involvement in HERVCOV validates our leadership in the field of HERVs,” said Jesús Martin-Garcia, CEO of GeNeuro. “We are grateful to be able to participate in this project with the main research centers in the EU and delighted with its results which can bring new personalized therapeutic solutions to patients.“.
HERVCOV is a collaborative research program benefiting from a grant of 6.85 million euros from the European call HORIZON-HLTH-2021-DISEASE (Personalized medicine and infectious diseases: understanding the individual host response to viruses) of the European Commission under the Horizon Europe framework programme. The research consortium includes research centers from 5 EU countries (INSERM (National Institute Of Health And Medical Research and INSERM TRANSFERT SA, France; Ethniko Kai Kapodistriako Panepistimio Athinon, Greece; Universita Degli Studi Di Roma Tor Vergata and Associazione Frascati Scienza, Italy; Instituto Aragones De Ciencias De La Salud, Spain; and Klinicki Bolnicki Centar Rijeka, Croatia, in collaboration with GeNeuro Innovation.
GeNeuro’s mission is to develop safe and effective treatments for neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which make up 8% of human DNA.
GeNeuro is based in Geneva, Switzerland, and has R&D facilities in Lyon, France. It holds the rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
This press release contains certain forward-looking statements and estimates regarding the financial condition, results of operations, strategy, plans and future performance of GeNeuro and the markets in which it operates. These forward-looking statements and estimates can be identified by words such as “anticipate”, “believe”, “may”, “could”, “estimate”, “expect”, “intend”, “is designed for”, “may”, “could”, “plan”, “potential”, “predict”, “goal”, “should” or the negative of these expressions and other similar expressions. They incorporate all subjects that are not historical facts. Forward-looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were believed to be reasonable at the time of when they were made, but which may prove to be incorrect. Events and results are difficult to predict and depend on factors beyond the company’s control. Accordingly, actual results, financial condition, performance and/or the achievements of GeNeuro or the industry r may turn out to be materially different from the future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Due to these uncertainties, no representation is made as to the accuracy or correctness of such forward-looking statements, forecasts and estimates. Further, forward-looking statements, forecasts and estimates speak only as of the date they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether whether as a result of new information, future events or otherwise, except as required by law.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220620005449/en/
President and CEO
+41 22 552 4800
Louis-Victor Delouvrier / Mathilde Bohin (investors)
+33 1 44 71 98 52
Arthur Rouille (media)
+33 1 44 71 94 98